HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase II study of recombinant human interferon-gamma in metastatic renal cell carcinoma.

Abstract
The efficacy of a low-dose regimen of human recombinant interferon-gamma was studied in 40 patients with metastatic or locally advanced renal cell carcinoma. Patients received 100 micrograms/m2/day as an infusion over 4 h. The intention was to find an active but tolerable regimen as a basis for future combination treatments with other cytokines or cytotoxic drugs. Activity of this low-dose schedule had been reported. In the absence of rapid progression, treatment was given for at least 3 months, and in case of stable disease it was continued for prolonged periods in order not to miss late remissions. Toxicity was generally mild, with fever and constitutional symptoms predominating. Therapeutic efficacy was low with only one partial remission. Three patients had stable disease over 6, 9, and 15 months. This low-dose schedule cannot be recommended for the treatment of renal cell cancer.
AuthorsU Bruntsch, P H de Mulder, W W ten Bokkel Huinink, M Clavel, A Drozd, S B Kaye, J Renard, M van Glabbeke
JournalJournal of biological response modifiers (J Biol Response Mod) Vol. 9 Issue 3 Pg. 335-8 (Jun 1990) ISSN: 0732-6580 [Print] United States
PMID2116500 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)
Chemical References
  • Recombinant Proteins
  • Interferon-gamma
Topics
  • Adult
  • Aged
  • Carcinoma, Renal Cell (drug therapy, secondary)
  • Drug Evaluation
  • Female
  • Humans
  • Interferon-gamma (administration & dosage, adverse effects, therapeutic use)
  • Kidney Neoplasms (drug therapy)
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Recombinant Proteins (administration & dosage, adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: